Login / Signup
[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation].
Lucie Houdou
Nicolas Kiavué
Published in:
Bulletin du cancer (2024)
Keyphrases
</>
metastatic breast cancer
locally advanced
estrogen receptor
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
signaling pathway
phase ii study
endoplasmic reticulum
breast cancer cells
clinical trial
study protocol